ALT logo

Altimmune (ALT) Company Overview

Profile

Full Name:

Altimmune, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 26, 2017

Indexes:

Not included

Description:

Altimmune is a biotechnology company focused on developing innovative treatments for infectious diseases and immune-related conditions. They create therapies that aim to enhance the body’s immune response, helping to improve health outcomes. Their research includes vaccines and treatments for various diseases, including respiratory and liver conditions.

Key Details

Price

$6.60

Annual Revenue

$426.00 K(+726.47% YoY)

Annual EPS

-$1.66(+8.29% YoY)

Annual ROE

-46.63%

Beta

2.02

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 20, 2017
Splits

Next split:

N/A

Recent split:

Sep 14, 2018

Analyst ratings

Recent major analysts updates

Feb 5, 25 HC Wainwright & Co.
Buy
Jan 23, 25 HC Wainwright & Co.
Buy
Jan 22, 25 HC Wainwright & Co.
Buy
Jan 8, 25 Stifel
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 12, 24 UBS
Buy
Aug 12, 24 B. Riley Securities
Buy
Jun 25, 24 B. Riley Securities
Buy
Jun 21, 24 Piper Sandler
Overweight
May 14, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Altimmune?
  • Does Altimmune pay dividends?
  • What sector is Altimmune in?
  • What industry is Altimmune in?
  • What country is Altimmune based in?
  • When did Altimmune go public?
  • Is Altimmune in the S&P 500?
  • Is Altimmune in the NASDAQ 100?
  • Is Altimmune in the Dow Jones?
  • When was Altimmune's last earnings report?
  • When does Altimmune report earnings?
  • Should I buy Altimmune stock now?

What is the ticker symbol for Altimmune?

The ticker symbol for Altimmune is NASDAQ:ALT

Does Altimmune pay dividends?

No, Altimmune does not pay dividends

What sector is Altimmune in?

Altimmune is in the Healthcare sector

What industry is Altimmune in?

Altimmune is in the Biotechnology industry

What country is Altimmune based in?

Altimmune is headquartered in United States

When did Altimmune go public?

Altimmune's initial public offering (IPO) was on May 26, 2017

Is Altimmune in the S&P 500?

No, Altimmune is not included in the S&P 500 index

Is Altimmune in the NASDAQ 100?

No, Altimmune is not included in the NASDAQ 100 index

Is Altimmune in the Dow Jones?

No, Altimmune is not included in the Dow Jones index

When was Altimmune's last earnings report?

Altimmune's most recent earnings report was on Nov 12, 2024

When does Altimmune report earnings?

The next expected earnings date for Altimmune is Mar 27, 2025

Should I buy Altimmune stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions